Almost 10 years ago, I made the decision to bring psychedelics back into modern medicine.
At the time, nearly every friend and business partner I spoke to responded with some version of: “You can’t do that.” (And that is the polite version.)
But my conviction in the therapeutic potential of these compounds was strong enough to push past the skepticism and move forward.
Shortly thereafter, I teamed up with George Goldsmith, Ekaterina Malievskaia, and @LarsWilde to found @COMPASSPathway.
And soon after, we launched atai - now @ataibeckley (Nasdaq: $ATAI) - as the psychedelic “mothership” designed to build a portfolio of differentiated, clinically validated psychedelic medicines.
AtaiBeckley still owns approx. 5% of Compass as per last filing.
Today, we are close to the moment we have been working toward for almost a decade.
Yesterday’s $CMPS update reconfirmed the expected timeline: a Q4 2026 NDA submission and an early 2027 commercial launch for COMP360 psilocybin. If this timeline holds, 2027 will mark the year in which psychedelic therapy becomes accessible to patients in the US within a regulated medical framework.
Looking back, I am especially proud of two things we have achieved:
1. The quality and rigor of the clinical evidence generated - with more than $1bn invested by Compass and AtaiBeckley into gold standard clinical trials across multiple psychedelic compounds and indications.
2. The fundamental shift in public perception - from “counterculture” to credible, FDA-grade drug development.
But the work is far from done.
In my view, the next phase of this sector will be driven less by broad sentiment and more by fundamentals.
Mental health is not a single disease category, and different root causes will require different therapeutic approaches. The key question is no longer whether psychedelics can show efficacy with an attractive side-effect profile - that has been clear to me from day one and at least for me was never in question - but whether individual drug candidates can fit into a scalable and reimbursable commercial model.
In other words: it will come down to duration, route of administration, patient convenience, and ultimately the practicality of delivering these therapies at scale.
Now that we have largely established that psychedelics do work, I believe investors will increasingly focus on those details - and that this is becoming a true stock-picker’s market.
I may be biased as founder and Chairman, but imo from a fundamental perspective, the choice is clear: AtaiBeckley.
Here is why:
@Evenios@runwayml I will presume they are hard at work on image to video. I would hope it's in deep testing and at the end of the beta. They gotta make sure it works good, and their systems can handle the usage, before a big public release. Geddings, like you, and many others,.. want this now.
What an outstanding 1st HY 2025 for @atai_life!
Ofc, there’s no reason to get lazy 😉 - the next six months (and beyond) will be packed with activity, more data readouts, and plenty more to come.
The future is psychedelic! $ATAI 🚀
Full update here:
https://t.co/jTXx98gJ7b
@C_Angermayer@BrendanBlumer@ThomasFarley@BonannoDavid@Bullish Christian, congrats to them, and to your being involved. ! Crypto / digital, is potent, wild, and powerful. Diligence matters. Empowerment matters. Of course this is connected to consciousness. / Josh
Honoured to be included in the @BBCWorld feature on cannabinoid medicine!
I contributed a video segment for the visual broadcast, and a longer audio commentary is on the radio show.
Canna-medicine is legitimate — and helps improve the health of millions of people worldwide. 🙏🏻
@grahamfarrar@glasshouse_ca .
You guys get to have fun, get high sometimes, grow tons of plant, make lots of $, and make beautiful things you can photograph.
& it took massive vision, tenacity and effort to get there.
Frickin' kudos!
/Josh
* Stay relentless on freeing all cannabis prisoners
@kylekazanceo
Great coverage of the upcoming Canadian Cannabis Leadership Summit from @MuggleheadMag. This interview with Paul McCarthy, President of the Cannabis Council of Canada, highlights the key challenges stifling growth in the cannabis industry: https://t.co/1aMHOXLjIJ